Viratek Inc.: The Costa Mesa drug development...
- Share via
Viratek Inc.: The Costa Mesa drug development company, a subsidiary of ICN Pharmaceuticals Inc., reported that its first-quarter profit increased to $471,000, or 3 cents a share, from $287,000, or 2 cents a share, for the like period last year. Revenue doubled, to $2.8 million from $1.4 million.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
